{
    "Trade/Device Name(s)": [
        "Vision BioSystems Progesterone Receptor Clone 16",
        "Novocastra Lyophilized Mouse Monoclonal Antibody",
        "Novocastra Liquid Mouse Monoclonal Antibody",
        "Novocastra Ready-to-Use Primary Antibody",
        "Origin Ready-to-Use Primary Antibody",
        "Bond Ready-to-Use Primary Antibody"
    ],
    "Submitter Information": "Vision BioSystems, Inc.",
    "510(k) Number": "K062615",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXZ"
    ],
    "Summary Letter Date": "JAN 2 9 2007",
    "Summary Letter Received Date": "September 5, 2006",
    "Submission Date": "August 25, 2006",
    "Regulation Number(s)": [
        "21 CFR 864.1860"
    ],
    "Regulation Name(s)": [
        "Immunohistochemistry Reagents and Kits"
    ],
    "Analyte Class(es)": [
        "anatomic pathology"
    ],
    "Analyte(s)": [
        "Progesterone receptor (PGR) antigen"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed paraffin embedded tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Manual use",
        "Ventana Medical Systems NexES Immunohistochemistry Staining Systems",
        "BenchMark Immunohistochemistry Staining Systems",
        "Vision BioSystems Bond-max system"
    ],
    "Method(s)/Technology(ies)": [
        "Immunohistochemistry",
        "Monoclonal antibody staining",
        "Light microscopy"
    ],
    "Methodologies": [
        "Qualitative detection by immunohistochemistry"
    ],
    "Submission Type(s)": [
        "Antibody",
        "Reagent",
        "Kit",
        "Primary Antibody"
    ],
    "Document Summary": "FDA 510(k) summary for Vision BioSystems Progesterone Receptor Clone 16 monoclonal antibody for qualitative detection of progesterone receptor in breast cancer tissue using immunohistochemistry",
    "Indications for Use Summary": "Qualitative identification of progesterone receptor antigen in formalin-fixed paraffin embedded tissue sections as an aid in the management, prognosis, and therapy prediction of breast cancer, to be interpreted by a qualified pathologist using appropriate controls and patient clinical history",
    "fda_folder": "Hematology"
}